Laboratorio de Química Médica, Instituto de Química Orgánica General, CSIC and Centro de Química Orgánica "Lora-Tamayo", CSIC, C/ Juan de la Cierva 3, 28006, Madrid, Spain.
Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, 40225, Düsseldorf, Germany.
Angew Chem Int Ed Engl. 2017 Oct 2;56(41):12765-12769. doi: 10.1002/anie.201706072. Epub 2017 Sep 1.
The therapy of complex neurodegenerative diseases requires the development of multitarget-directed drugs (MTDs). Novel indole derivatives with inhibitory activity towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H receptor (H3R) were obtained by optimization of the neuroprotectant ASS234 by incorporating generally accepted H3R pharmacophore motifs. These small-molecule hits demonstrated balanced activities at the targets, mostly in the nanomolar concentration range. Additional in vitro studies showed antioxidative neuroprotective effects as well as the ability to penetrate the blood-brain barrier. With this promising in vitro profile, contilisant (at 1 mg kg i.p.) also significantly improved lipopolysaccharide-induced cognitive deficits.
复杂神经退行性疾病的治疗需要开发多靶标导向药物(MTD)。通过将神经保护剂 ASS234 进行优化,得到了具有乙酰/丁酰胆碱酯酶和单胺氧化酶 A/B 抑制活性以及组胺 H 受体(H3R)抑制活性的新型吲哚衍生物,同时引入了公认的 H3R 药效团模式。这些小分子命中物在靶标上表现出平衡的活性,大多数在纳摩尔浓度范围内。额外的体外研究表明它们具有抗氧化神经保护作用以及穿透血脑屏障的能力。凭借这一有前景的体外特征,化合物(腹腔注射 1mg/kg)也显著改善了脂多糖诱导的认知缺陷。